Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Moderna's new mRNA flu vaccine shows 26.6% better protection than standard vaccines, notably in older adults.

flag Moderna's new mRNA flu vaccine, mRNA-1010, showed strong results in a Phase 3 trial, providing 26.6% more protection against the flu than a standard flu vaccine. flag It was especially effective in adults 65 and older, with a 27.4% improvement. flag The vaccine was effective across different age groups and health conditions. flag Moderna plans to present the full trial data and publish the results in a peer-reviewed journal.

5 Articles

Further Reading